These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34805375)

  • 1. EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction.
    Wagdy K; Nagy S
    Glob Cardiol Sci Pract; 2021 Oct; 2021(3):e202117. PubMed ID: 34805375
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
    Coats AJS; Butler J; Tsutsui H; Doehner W; Filippatos G; Ferreira JP; Böhm M; Chopra VK; Verma S; Nordaby M; Iwata T; Nitta D; Ponikowski P; Zannad F; Packer M; Anker SD
    J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):412-424. PubMed ID: 38158636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S
    Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
    Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
    Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors.
    Heath R; Johnsen H; Strain WD; Evans M
    Diabetes Ther; 2022 Feb; 13(2):241-250. PubMed ID: 35084695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Starr JA; Pinner NA
    Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
    Butler J; Usman MS; Filippatos G; Ferreira JP; Böhm M; Brueckmann M; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Senni M; Sumin M; Verma S; Zaremba-Pechmann L; Pocock SJ; Packer M; Anker S
    JAMA Cardiol; 2023 Jul; 8(7):640-649. PubMed ID: 37223933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial.
    Böhm M; Butler J; Krawczyk M; Mahfoud F; Haring B; Filippatos G; Ferreira JP; Pocock SJ; Brueckmann M; Ofstad AP; Schüler E; Wanner C; Verma S; Packer M; Anker SD;
    Eur J Heart Fail; 2023 Aug; 25(8):1375-1383. PubMed ID: 37278451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
    Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction.
    Brust-Sisti L; Rudawsky N; Gonzalez J; Brunetti L
    Pharmacy (Basel); 2022 Nov; 10(6):. PubMed ID: 36548322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
    Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
    ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.
    Hallinen T; Kivelä S; Soini E; Harjola VP; Pesonen M
    Clinicoecon Outcomes Res; 2023; 15():1-13. PubMed ID: 36636485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Bhm M; Anker S; Mahfoud F; Lauder L; Filippatos G; Ferreira JP; Pocock SJ; Brueckmann M; Saloustros I; Schler E; Wanner C; Zannad F; Packer M; Butler J
    Eur Heart J; 2023 Feb; 44(5):396-407. PubMed ID: 36478225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible.
    Sciatti E; Gori M; D'elia E; Iacovoni A; Senni M
    Eur Heart J Suppl; 2022 Nov; 24(Suppl I):I153-I159. PubMed ID: 36380802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.